Collegium Pharmaceutical (COLL) Interest & Investment Income (2016 - 2026)

Collegium Pharmaceutical's Interest & Investment Income history runs 11 years deep, the most recent figure standing at $3.7 million for Q1 2026.

• On a quarterly basis, Interest & Investment Income rose 66.56% year-over-year to $3.7 million in Q1 2026; TTM through Mar 2026 was $12.8 million, a 9.01% increase from a year earlier, with the FY2025 full-year figure at $11.3 million, down 19.23% from the prior year.
• Interest & Investment Income improved to $3.7 million in Q1 2026 per COLL's latest filing, from $3.6 million in the prior quarter.
• Across five years, Interest & Investment Income topped out at $4.5 million in Q3 2023 and bottomed at $4000.0 in Q1 2022.
• The 5-year median for Interest & Investment Income is $3.1 million (2025), against an average of $2.7 million.
• Across the five-year window, Interest & Investment Income surged 80440.0% in 2023 and tumbled 57.89% in 2024, its largest moves.
• Year by year, Interest & Investment Income stood at $1.0 million in 2022, then soared by 318.99% to $4.3 million in 2023, then tumbled by 57.89% to $1.8 million in 2024, then soared by 96.74% to $3.6 million in 2025, then grew by 3.96% to $3.7 million in 2026.
• Per Business Quant, the three latest COLL Interest & Investment Income figures stand at $3.7 million (Q1 2026), $3.6 million (Q4 2025), and $3.1 million (Q3 2025).